Physicochemical Properties
| Molecular Formula | C13H10O3 |
| CAS # | 1314798-31-6 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | To limit the production of DNA fragments and avoid being taken up by Topo II toxins, MSN8C keeps supercoiled DNA from entering the catalytic cycle [1]. MSN8C (1-10 μM, 24 h) increases caspase-3 expression in a dose-dependent manner to cause apoptosis [1]. In HL-60 cells, MSN8C (1, 5, 10, 20 μM, 12 hours) boosts the activities of caspase-8 and caspase-9 [1]. Eleven distinct human tumor cell lines can be inhibited by MSN8C (48 hours) with an average IC50 value of 2.60 µM[1]. The human breast cancer cell lines MCF-7/Adr, which is resistant to doxorubicin, and HL-60/MX2, which is resistant to mitoxantrone, have significant anti-proliferative effects when exposed to MSN8C [1]. |
| ln Vivo | In the A549 tumor xenograft model, MSN8C (10 mg/kg, intraperitoneal injection, two days apart, for two weeks) suppresses tumor growth with less toxicity[1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: HL-60 cells Tested Concentrations: 10 μM Incubation Duration: 1 h Experimental Results: diminished γ-H2AX expression levels. Weakened the production of γ-H2AX by VP-16. Western Blot Analysis[1] Cell Types: HL-60 cells Tested Concentrations: 1, 5, 10, 20 μM Incubation Duration: 1, 5, 10, 20 μM Experimental Results: Induced caspases-3 express in a dose-dependent manner. Apoptosis Analysis[1] Cell Types: HL -60 cells Tested Concentrations: 5, 10 μM Incubation Duration: 12 h Experimental Results: Promoted caspase-8 and caspase-9 activity in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: A549 tumor xenograft model, female BALB/c nude mice[1] Doses: 10 mg/kg Route of Administration: intraperitoneal (ip) injection (ip), two-day intervals for 2 weeks Experimental Results: Inhibits tumor with the tumor weight inhibition (TWI) value of 74.2%. |
| References | [1]. Jie-Bin Ou, et al. MSN8C: A Promising Candidate for Antitumor Applications as a Novel Catalytic Inhibitor of Topoisomerase II. Molecules. 2023 Jul, 28(14). |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |